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fertility‐sparing	approach.	The	 secondary	aim	was	 to	define	 clinicopathologic	 fea‐
tures	of	atypical	polypoid	adenomyoma.













tage.	 Transcervical	 resection	 showed	 significantly	 higher	 initial	 response	 rates	 (P 
from	<.001	to	.023)	than	any	other	treatment.	Transcervical	resection	and	transcervi‐
cal	 resection+hormonal	 therapy	 showed	 significantly	 lower	 progression	 rates	
(P < .001),	and	higher	final	complete	response	rates	(P < .001)	than	any	other	treat‐
ment.	No	significant	differences	were	found	in	the	rates	of	pregnancy	(P = .533‐.647)	
or	 recurrence	 (P = .052‐.475).	 Among	 the	 different	 transcervical	 resection	 tech‐
niques,	 the	 4‐step	 transcervical	 resection	 showed	 significantly	 lower	 rates	 of	
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1  | INTRODUC TION
Atypical	 polypoid	 adenomyoma	 or	 atypical	 polypoid	 adenomy‐











However,	 since	 APA	 affects	 premenopausal	 women	 in	 most	
cases,5‐7	 a	 fertility‐sparing	 approach	 appears	 necessary.	 Several	
conservative	 treatments	 have	 been	 adopted,	 including	 progestin‐
based	 hormonal	 therapy	 (HT)	 with	 or	 without	 maintenance	 (M),	
hysteroscopic	 transcervical	 resection	 (TCR),	dilation	and	curettage	
(D&C)	or	the	combination	of	HT	with	TCR	or	D&C.1,5‐14



























of	 Sciences,	 Scopus,	 ClinicalTrial.gov,	 OVID,	 Google	 Scholar	 and	
Cochrane	Library	as	electronic	databases.	The	relevant	articles	were	
searched	 from	 the	 inception	 to	May	 2018	 using	 a	 combination	 of	
the	 following	 text	words	 and	 all	 their	 synonyms	 found	on	Medical	
SubHeading	 (MeSH)	 vocabulary:	 “atypical	 polypoid	 adenomyoma”;	
“APA”;	 “adenofibroma”;	 “adenomyofibroma”;	 “uterus”;	 “uterine”;	
“endometrial”;	 “myometrium”;	 “treatment”;	 “fertility‐sparing”;	 “con‐
servative”;	 “MPA”;	 “medroxyprogesterone”;	 “LNG‐IUD”;	 “Mirena”;	
“levonorgestrel”;	 “progesterone”;	 “progestogen”;	 “progestin”;	
progression	(P = .002)	and	recurrence	(P = .013)	than	other	techniques.	Limitations	to	
our	results	were	the	retrospective	design	of	the	studies	and	the	relatively	small	sam‐
ple	size,	due	to	the	rarity	of	atypical	polypoid	adenomyoma.
Conclusions: Based	on	 its	effectiveness	and	safety,	 transcervical	 resection	may	be	
the	 first‐line	 fertility‐sparing	 treatment	 for	 atypical	 polypoid	 adenomyoma.	 In	 par‐
ticular,	4‐step	transcervical	resection	showed	the	best	results.	Given	the	risk	of	recur‐
rence,	progression	and	coexistent	atypical	hyperplasia	or	cancer,	follow‐up	biopsies	
are	 advisable.	When	 fertility	 preservation	 is	 not	 required,	 hysterectomy	might	 be	
advisable.




Transcervical	 resection	 should	 be	 the	 first‐line	 fertility‐
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Comparisons	 (C)	 were	 performed	 among	 conservative	 treat‐
ments	(see	data	analysis).



































points	appropriate	 to	 the	aim	 (ie,	unambiguous	explanation	of	 the	
criteria	used	to	measure	outcomes);	(5)	unbiased	assessment	of	the	
study	endpoint	(ie,	the	study	endpoint	was	assessed	without	bias);	
(6)	 follow‐up	 period	 appropriate	 to	 the	 aim	 (ie,	 the	 follow	up	was	
sufficiently	long	to	allow	the	assessment	of	the	main	endpoint),	(7)	
loss	to	follow	up	less	than	5%	(ie,	no	more	than	5%	of	patients	were	
lost	 to	 follow	up).	Review	authors’	 judgments	were	categorized	as	




























3.2 | Risk of bias assessment

















formed	 histological	 examination	 only	 when	 ultrasonographic	
findings	 were	 suspicious,	 or	 if	 they	 did	 not	 specify	 whether	











between	 16.6	 and	 28.7	kg/m2;	 85.5%	 of	women	were	 premenopausal	
and	62.9%	were	nulliparous;	35.4%	had	menstrual	cycle	irregularity	and	
18.6%	were	infertile.	The	most	common	symptoms	were:	abnormal	uter‐













cervix	 in	11.5%.	APA	diameter	 ranged	between	1	and	70	mm;	 the	

















A	 total	 of	 169	 patients	 were	 conservatively	 treated:	 91	 (53.8%)	
women	 underwent	 TCR,	 39	 (23.1%)	 TCR+HT,	 18	 (10.7%)	 HT	 (of	
whom	5	with	M),	17	(10.1%)	D&C,	2	(1.2%)	D&C+HT,	and	2	(1.2%)	










suspicious.7,12,14	 In	 two	 studies	 the	 follow	 up	 was	 based	 on	 D&C	
without	specifying	the	interval	between	each	D&C.5,10	Three	stud‐
ies 1,6,11	did	not	report	details	about	follow	up.	The	follow‐up	time	
ranged	 between	 1	 and	 276	months.	 CA125	 and	 CA19.9	 were	 as‐
sessed	in	only	one	study,	showing	normal	values.7
Details	about	treatments	and	follow	up	are	shown	in	Table	3.
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disease‐free	 interval	 ranging	 between	 1	 and	 60	months,	 and	 final	
complete	response	in	69.9%.	No	death	from	APA	was	reported.
Initial	response	was	significantly	more	common	in	TCR	(98.7%)	
than	HT	(77.7%;	P = .004),	TCR+HT	(69.2%;	P < .001)	or	D&C	(75%;	
P = .023).
The	 rate	 of	 progression	 to	 cancer	 did	 not	 significantly	 differ	
between	 TCR	 (10.8%)	 and	 TCR+HT	 (5.1%;	 P = .49),	 but	 TCR	 and	
TCR+HT	showed	significantly	fewer	progressions	than	HT	without	
M	(69.2%;	P < .001).
No	 significant	 differences	 in	 the	 recurrence	 rates	 were	 found	
between	TCR+HT	 (17.9%)	 and	TCR	 (29.8%;	P = .191),	D&C	 (36.4%;	
P = .475)	or	HT	without	M	(44.4%;	P = .052).
Concerning	 final	 complete	 response	 rates,	 no	 significant	 dif‐
ferences	 were	 found	 between	 TCR	 (77.3%)	 and	 TCR+HT	 (82.1%;	
P = .634),	 but	 both	 approaches	 showed	 significantly	 higher	 rates	
than	HT	without	M	(15.4%;	P < .001).
Due	to	 the	 low	number	of	patients,	D&C	and	HT+M	could	not	





ported	 in	detail	 in	Table	4;	details	about	 recurrent	APA	are	shown	
in	Table	S1;	additional	oncologic	outcomes	are	reported	in	Table	4.
3.9 | Reproductive outcomes of 
conservative treatments
Pregnancy	was	 achieved	 in	 25.3%	 of	 all	 patients	 who	 underwent	
conservative	treatment.	No	significant	differences	in	the	pregnancy	
rates	were	found	between	HT	with	M	 (40%)	and	TCR+HT	 (30.8%;	





3.10 | Comparison among TCR techniques
The	 4‐step	 technique	 showed	 the	 best	 results	 (100%	 initial	 response,	
83.3%	final	complete	response,	10%	recurrence,	0%	progression).14	The	
4‐step	TCR	showed	significantly	lower	progression	and	recurrence	rates	







rate	 than	 any	 other	 conservative	 treatment.	 TCR	 and	 TCR+HT	
showed	 higher	 final	 complete	 response	 rate	 and	 lower	 progres‐
sion	rate	than	HT	without	M.	No	significant	differences	were	found	
among	 the	 several	 conservative	 approaches	 regarding	 recurrence	








were	 premenopausal	 (85%)	 and	 nulliparous	 (62.9%),	 empha‐
sizing	 the	 importance	 of	 an	 effective	 and	 safe	 fertility‐sparing	
treatment.	Regarding	symptom	presentation,	APA	was	rarely	an	


























consensus	 about	 the	optimal	 treatment	 (conservative	or	 non‐con‐








Several	 conservative	 approaches	were	 described	 in	 the	 literature,	
but	it	is	unclear	which	one	should	be	preferred.
In	 our	 study,	 initial	 response,	 final	 complete	 response	 and	 preg‐
nancy	rates	were	used	to	estimate	the	effectiveness	of	the	conservative	
6  |     RAFFONE Et Al.
treatments,	and	progression	and	recurrence	rates	were	used	to	define	
the	safety.




patients,	 progression	 in	 10.8%,	 final	 complete	 response	 in	 77.3%,	
recurrence	in	29.8%	and	pregnancy	in	21.1%.
Remarkably,	TCR	showed	significantly	higher	rates	of	 initial	re‐













TA B L E  1  Patient	characteristics




Age years, mean 
(range)









n (%) Symptoms (%) Other pathologies (%)
Nomura	
et al9
Japan Retrospective 18 2001‐2011 Consecutive 33.6	(26‐45) 21.9	(18.3‐27.6) 18	(100) 7	(38.8) 18	(100) ‐ ‐ ‐













Chen	et	al13 China Retrospective 10 2004‐2016 Consecutive 30	(23‐40) ‐ ‐ ‐ 7	(70) 9	(90) 2	hypermenorrhea;	2	metror‐
rhagia;	2	pelvic	mass;	1	
irregular uterine bleeding; 1 
menostaxis;	1	secondary	
infertility;	1	vaginal	bleeding
2 ovarian cysts; 1 uterine adenomy‐
























USA Retrospective 55 ‐ Consecutive 39.9	(25‐73) 31 obese  
patients	(56.4)
53	(96) ‐ 28	(51) 15	(27.3) most common: abnormal uterine 




sclerocystic ovaries; 2 endometriosis; 





Japan Retrospective 6 1991‐1994 Consecutive 33	(22‐48) ‐ 6	(100) ‐ 6	(100) ‐ 6	abnormal	uterine	bleeding 1	history	of	uterine	tuberculosis;	1	
uterine leiomyomas




Mazur1 USA Retrospective 5 ‐ Consecutive 38	(33‐44) ‐ 5	(100) ‐ 3	(60) ‐ 5 abnormal uterine bleeding 2	hypertension;	2	diabetes;	1	uterine	
leiomyomas


































diagnosed	with	APA.	 In	 fact,	 both	modality	 and	 timing	of	 follow	up	
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were	different	among	the	studies.	In	three	studies,8,9,13	D&C	or	hys‐





tion would be advisable.
The	interval	between	follow‐up	visits	ranged	from	3	months	to	
1	year.	 It	 should	be	noted	 that	up	 to	 four	 recurrences,	with	 a	dis‐
ease‐free	 interval	up	 to	60	months,	were	described,	and	1	patient	
needed	to	undergo	hysterectomy	84	months	after	the	beginning	of	
the	 conservative	 treatment.	 Therefore,	 a	 long	 follow‐up	 duration	
should	be	advisable.	The	follow‐up	modality	described	by	Nomura	
et	al	appears	to	be	a	safe	approach,8,9	consisting	of	dilation	and	cu‐




sessed,	 reporting	 normal	 values7;	 however,	 evidence	 for	 their	 use	
is	lacking.	Instead,	it	is	possible	that	some	markers	associated	with	




Nomura	et	al9 HT 2/5M	(40)	2/13	(15.4) ‐
Ma	et	al14 TCR ‐ ‐
























Longacre	et	al6 TCR+HT 5/29	(17.2) 5	patients	with	recurrent	or	persistent	lesions	subse‐
quently	became	pregnant	and	delivered	normal	full‐term	
infants,	including	one	patient	who	bore	two	children
Fukunaga	et	al10 D&C+HT	TCR ‐ ‐
Young et al5 D&C	TCR ‐ ‐
Mazur1 D&C 1/5	(20) ‐


















Limitations	 to	our	 results	might	be	 the	 retrospective	design	of	
the	included	studies,	the	relatively	small	sample	size	and	the	lack	of	
studies	that	compares	different	treatments.	Such	limitations	partic‐









Given	 the	 risk	 of	 recurrence	 and	 progression,	 APA	 might	 be	
treated	by	hysterectomy	in	patients	with	no	desire	for	pregnancy.	







first	 2	years,	 every	 4‐6	months	 for	 another	 3	years,	 and	 once	 a	
year	thereafter.
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